[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 15, 2000

Bisphosphonate Therapy and Vascular Calcification—Reply

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(11):1424-1425. doi:10.1001/jama.283.11.1421

In Reply: Serious events reported in this study were defined in accordance with regulatory guidelines.1 As noted in Table 3 of our article, the overall incidence of serious adverse events reported was similar between the placebo (27%) and 5-mg risedronate (29%) groups.

We performed a safety analysis focusing on major cardiovascular events reported during the study. Based on this analysis, the most common events occurred at similar incidences between treatment groups. Cardiovascular events reported at a cumulative incidence of more than 1% were right heart failure (placebo, 1.6%; risedronate, 1.8%), myocardial infarction (placebo, 1.6%; risedronate, 1.5%), and cerebrovascular accident (placebo, 1.0%; risedronate, 1.4%).

First Page Preview View Large
First page PDF preview
First page PDF preview
×